Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Bayer
研究概览
简要总结
Larotrectinib expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion, who are ineligible for an ongoing larotrectinib clinical trial or have other considerations that prevent access to larotrectinib through an existing clinical trial. Gene fusion occurs when a gene is made by joining parts of two different genes. NTRK gene fusion can lead to the development of solid tumors in a variety of tissue types. The study drug larotrectinib blocks the action of the NTRK gene fusion.
Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion who are unresponsive to current standard treatment for their condition and also are unable to participate in ongoing clinical trials.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion
- •Subjects are unable to participate in an ongoing larotrectinib clinical trial
- •Medically suitable for treatment with larotrectinib
排除标准
- •Currently enrolled in an ongoing clinical study of larotrectinib or another TRK inhibitor